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BRIEF COMMUNICATIONS 
APROTININ AND AORTIC CANNULA THROMBOSIS 
Richard Gitter, MD, a Peter Alivizatos, MD, a John Capehart, MD, a Michael Ramsay, MD, b and G. Kimble Jett, MD, a 
Dallas, Tex. 
Aprotinin has been advocated to reduce perioperative 
blood loss in patients undergoing cardiopulmonary b pass 
(CPB).I, 2 Its effect on the coagulation cascade has been 
investigated by many researchers and its clinical effective- 
ness has been documented. 3'4 However, the potential 
adverse sequelae of potent antifibrinolytic therapy has 
received less attention. 
Thrombus formation has been reported with pulmonary 
artery catheters after aprotinin administration. 5 Throm- 
bus formation in the aortic outflow cannula, reported 
herein, represents a unique complication of antifibrino- 
lytic therapy and merits attention. 
Case report. A 64-year-old woman weighing 78 kg, with 
end-stage congestive cardiomyopathy, underwent cardiac 
transplantation. Two million kallikrein inactivator units 
(FdU) of aprotinin was bolused intravenously before the 
initial skin incision, followed by a continuous infusion at 
500,000 KIU/hr. Additionally, another 2 million KIU of 
aprotinin was added to the extracorporeal circuit as a 
priming dose before institution of CPB. Before CPB, 
heparin (4 mg/kg) was administered and an activated 
clotting time (ACT) of 600 seconds obtained. (ACT was 
measured in celite test tubes in an automated evice 
[Hemochron, International Technidyne Corp., Edison, 
N.J.]. ACTs during CPB ranged between 600 and 963 
seconds.) After implantation of an 18-year-old donor 
heart, the patient had cardiac graft dysfunction resulting 
in cardiogenic shock and hypotension. Mechanical sup- 
port with intraaortic balloon counterpulsation a d aggres- 
sive inotropic support were instituted. The patient was 
weaned from CPB and protamine was administered. 
After decannulation and observation in the operating 
room for 4 hours, the patient's cardiac hcmodynamics 
worsened. She was therefore reheparinized (4mg/kg) and, 
with the aid of CPB, ABIOMED BVS 5000 (ABIOMED 
Cardiovascular, Inc., Danvers, Mass.) biventricular assist 
devices (BVADs) were inserted. A new extracorporeal 
circuit and new cannulas were used. Aprotinin was not 
rebolused or added to the prime of the new CPB circuit, 
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but the continuous infusion was continued throughout the 
period of observation and insertion of BVADs. The CPB 
time required for BVAD insertion was 105 minutes. ACTs 
measured uring the second CPB time ranged from 984 to 
1199 seconds. After separation from CPB and institution 
of biventricular support, the patient had stable hemody- 
namics. The aortic cannula was left in place for approxi- 
mately 50 minutes after cessation of CPB for volume 
administration. Heparin was reversed with protamine and 
the continuous infusion of aprotinin was continued. The 
pump sucker was discontinued immediately with cessation 
of CPB and start of protamine administration. On re- 
moval of the aortic cannula, thrombus was noted in the 
lumen of the outflow cannula, which extended through the 
purse-string suture into the aorta. The thrombus was 
extracted from the aorta before the purse-string suture 
was secured. The venous cannula removed earlier had no 
thrombus. 
The patient's hemodynamic status tabilized with biven- 
tricular support after the operation. The next morning she 
had a dilated and fixed left pupil and was neurologically 
unresponsive. A computed tomographic scan revealed a
large infarct in the left hemisphere with generalized 
cerebral edema and tentorial herniation. Hemodynamic 
support was withdrawn at this point at the family's re- 
quest. After termination of support, no thrombus was 
noted in the BVADs. 
Discussion. Aprotinin is a potent nonspecific protease 
inhibitor that exerts its antifibrinolytic effect by kallikrein 
inhibition, thereby hindering progression of the comple- 
ment and coagulation cascades. It is further believed to 
preserve platelet function by its effect on glycoprotein IB, 
the platelet membrane receptor for von Willebrand fac- 
tor.l.2 High-dose infusion of this agent initiated before 
complex cardiac operations has been shown to reduce 
intraoperative and postoperative blood loss. This effect 
appears to be independent of systemic heparinization. 3' 4
Aprotinin has not been shown to be prothrombotic. 
OutflOW cannula thrombus after administration f apro- 
tinin has not been previously described. Although early 
thrombus formation was reported with pulmonary artery 
catheters after aprotinin administration, 5 there is a ques- 
tion of underheparinization in that report, because the 
ACT was only 497 seconds. Our patient had adequate 
anticoagulation. I  addition, the pump sucker was imme- 
diately withdrawn from the field with protamine adminis- 
tration. New aortic and venous cannulas, as well as a new 
extracorporeal circuit, were used for BVAD insertion. We 
believe that leaving the aortic cannula for volume admin- 
istration for a period of time after CPB contributed to 
stasis and thrombus formation within the aortic cannula. 
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Earlier removal of the aortic cannula may have prevented 
thiS complication. 
Thrombus formation, both microscopic and macroscopic, 
has the potential for disastrous complications in patients 
receMng antifibrinolytic therapy. The risk of thrombus for- 
mation may be increased with stasis of blood. We would 
therefore recommend early removal of intravascular cathe- 
ters when antifibrinolytic therapy has been instituted. 
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RECURRENT THROMBOSIS OF BIVENTRICULAR-SUPPORT DEVICES ASSOCIATED WITH 
ACCELERATED INTRAVASCULAR COAGULATION AND INCREASED HEPARIN REQUIREMENTS 
George J. Despotis, MD, Vladimir Levine, MD, Alexander Alsoufiev, MD, Heinrich Joist, MD, PhD, 
Lawrence T. Goodnough, MD, and Michael Pasque, MD, St. Louis, Mo. 
Thrombus formation in ventricular-assist devices has 
occurred espite apparently adequate anticoagulant ther- 
apy. The factors and mechanisms involved in the devel- 
opment of this potentially serious complication are poorly 
understood. We describe the case of a patient in whom 
multiple episodes of thrombosis developed in biventricu- 
lar-support devices (BIVADs) used as a bridge to cardiac 
transplantation. These episodes were associated with accel- 
erated intravascular coagulation and increased heparin re- 
quirements, which seemed to be favorably affected by ad- 
ministration of fresh-frozen plasma (FFP). 
A 44-year-old white man came to our tertiary care 
institution for cardiac transplantation evaluation after a 
recent episode of congestive heart failure that was unrespon- 
sive to aggressive medical management. After an 8-year 
history of myocardial infarctions and progressive heart fail- 
ure, he began a period of rapid deterioration 4 months 
before admission, at which time evaluation revealed end- 
stage ischemic cardiomyopathy. Cardiac catheterization 
demonstrated global left ventricular hypokinesia with an 
ejection fraction of 7% and severe coronary artery dis- 
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ease; transthoracic e hocardiography revealed moderately 
severe mitral and moderate tricuspid regurgitation. Previ- 
ous management of his cardiac ondition included inotro- 
pic support, afterload reduction, and diuresis. Laboratory 
evaluation showed elevated transaminase l vels, reduced 
total protein level, reduced albumin level, and increased 
bilirubin level and prothrombin time, consistent with 
chronic, passive liver congestion. 
On arrival, the patient was noted to be in severe 
congestive heart failure accompanied by tachycardia t 
150 beats/rain as a result of atrial flutter with a 2:1 
conduction block. Initial treatment consisted of cardiover- 
sion to sinus rhythm followed by intravenous administra- 
tion of nipride, dobutamine, and amrinone and subcuta- 
neous injection of heparin (5000 U every 12 hours). The 
patient's condition worsened uring the next several days, 
with development of cardiogenic shock (systolic blood 
pressure, 70 to 80 mm Hg; pulmonary artery wedge 
pressure, 38 mm Hg; cardiac index <1.5) despite large doses 
of dobutamine and amrinone necessitating bypass resus- 
citation on day 9 (Fig. 1). Subsequently, ABIOMED 
(ABIOMED Cardiovascular, Inc., Danvers, MasS.) biven- 
tricular support devices (BIVADs) were inserted as a 
bridge t ° transplantation. After insertion of the BIVADs, 
the patient had anticoagulation with a continuous infusion 
of heparin at 1800 to 2100 U/hr to maintain the celite 
activated clotting time (ACT) between 180 and 200 sec- 
onds. During days 9 through 19, a progressive increase in 
heparin requirements (4000 U/hr) was noted. On day 19, 
clot formation in the BIVAD circuit necessitated emer- 
gency operative replacement of the BIVAD system (Fig. 
1). Recurrent BIVAD thrombosis was noted on day 20, 
necessitating a second replacement of the BIVAD system. 
In light of these events and a decrease in the platelet 
